John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

See the incredible transformation of FrenchieFries' parents' house into a million-dollar dream home! Featuring a full ...

The H5N1 avian influenza virus has infected birds and mammals around the world. As of June 2025, 70 people have been infected ...

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical ...

Texas Parks and Wildlife wants your opinion on a new license plate design showing a horned lizard.

Artificial intelligence (AI) drug development corporation GALAXIS and drug development corporation HANALL BIOPHARMA will begin joint research to develop a new anti-cancer antibody treatment. GALAXIS ...

Researchers at MIT and the Scripps Research Institute have shown that they can generate a strong immune response to HIV with ...